News

News

FDA Expands Rivaroxaban’s Indication to Include Hospitalized Patients

The U.S. Food and Drug Administration (FDA) approved the direct oral anticoagulant rivaroxaban for the prevention of venous thromboembolism (VTE) in hospitalized, acutely ill...
ASH Directions

ASH Commissions Study of U.S. Fellows, Honors Stanley Schrier with 2019 Exemplary Service Award,...

ASH Commissions 3-Year Longitudinal Study of U.S. Fellows The American Society of Hematology (ASH), in partnership with the Fitzhugh Mullan Institute for Health Workforce Equity...

Patients’ Humoral Immunity Is Preserved, With Low Rates of Viral Infections, After Anti-CD19 CAR...

The two commercially available chimeric antigen receptor (CAR) T-cell products both target cells expressing the CD19 antigen, which is present on malignant and nonmalignant...

National Academy of Medicine Releases Report on Clinician Burnout

In a newly published report, the National Academy of Medicine called for systematic changes from health care organizations, educational institutions, and all levels of...

Updated Romiplostim Label Supports Earlier Use in ITP

The U.S. Food and Drug Administration (FDA) granted approval to a supplemental Biologics License Application for romiplostim that updates the drug’s label to include...

Vincristine Shortages Expected to Continue Into 2020

The U.S. is experiencing a shortage of the chemotherapy drug vincristine, a critical treatment for leukemias, lymphomas, and brain tumors in adult and pediatric...

European Commission Approves Gilteritinib for FLT3-Mutated, Relapsed/Refractory AML

The European Commission approved the oral FLT3/AXL inhibitor gilteritinib as a single agent for the treatment of adult patients with relapsed or refractory acute...
WIB_icon

Emicizumab Lowers Bleeding Rates in Children With Hemophilia A and Inhibitors

Once-weekly treatment with emicizumab prophylaxis led to low bleeding rates in children with hemophilia A and factor VIII (FVIII) inhibitors, with more than three-quarters...
WIB_icon

Moderate-Intensity Endurance Training Improves Skeletal Microvasculature in Patients with Sickle Cell Disease

An endurance exercise training program of moderate intensity may reverse some of the microvascular deficits of skeletal microvasculature in patients with sickle cell disease...

Chemotherapy-Free Regimen of ATRA Plus Arsenic Trioxide Improves Survival in APL

Updated results from the APL0406 study suggest that the combination of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) was associated with greater long-term...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.